Drug General Information (ID: DDIXZKREGQ)
Drug Name			Anistreplase		Drug Info		Icosapent		Drug Info
Drug Type		Protein/peptide				Small molecule
Therapeutic Class		Thrombolytics				Dietary Supplement

Mechanism of Anistreplase-Icosapent Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Anistreplase				Icosapent
Mechanism		Risk of bleeding Thrombolytic agent				Risk of bleeding Antiplatelet/anticoagulant effects
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Anistreplase and Icosapent

Recommended Action
Management		In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Li XL, Steiner M "Fish oil: a potent inhibitor of platelet adhesiveness." Blood 76 (1990): 938-45. [PMID: 2118400]
3	Product Information. Vascepa (icosapent). Amarin Pharmaceuticals Inc, Warren, NJ.